cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2021.10.n1734cardio-1734Research ArticleМНЕНИЕ ЭКСПЕРТАМнение по проблеме. Спиронолактон: новый поворот старой историиExpert opinion. Spironolactone: a new twist on an old storyhttps://orcid.org/0000-0002-8160-5612ОрловаЯ. А.OrlovaYa. A.

Руководитель отдела Возраст-ассоциированных заболеваний

Head of the Department of Age-Associated Diseases Medical Research Center of Moscow State University M.V. Lomonosova

5163002@bk.ruhttps://orcid.org/0000-0001-7992-6081БеграмбековаЮ. Л.BegrambekovaYu. L.

Ведущий научный сотрудник

Leading Researcher Medical Research and Education Center of Moscow State University M.V. Lomonosova

julia.begrambekova@ossn.ruПлисюкА. Г.PlisukA. G.

старший научный сотрудник

Senior Researcher

apl.cardio@yandex.ru«Медицинский научно-образовательный центр МГУ им. М.В.Ломоносова», Москва, Россия МГУ им. М. В. Ломоносова, факультет фундаментальной медицины, Москва, РоссияРоссияMedical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, RussiaRussian Federation202130102021611099103Copyright © Kardiomag, 20212021KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/1734

В материале представлены последние данные о возможностях более широкого применения антагонистов минералокортикоидных рецепторов по имеющимся показаниям, а также расширении показаний к применению этой группы препаратов в контексте новой коронавирусной инфекции 2019 года. Обсуждаются перспективы более широкого выявления альдостеронизма с помощью нового диагностического подхода, включающего дополнительную оценку реакции артериального давления на спиронолактон.

The article presents recent data on possibilities of a broader use of mineralocorticoid receptor antagonists for existing indications and of expanding indications for the use of this pharmaceutical group in the context of the novel coronavirus infection COVID-19. The authors discussed prospects for expanded detection of aldosteronism using a new diagnostic approach, including an additional evaluation of blood pressure response to spironolactone.

СпиронолактонАГCOVID-19альдостеронизмSpironolactonearterial hypertensionCOVID-19aldosteronismКонфликт интересов не заявлен.No conflict of interest is reported.ReferencesZannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000;102(22):2700–6. PMID: 11094035Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000;102(22):2700–6. PMID: 11094035Скворцов А.А., Нарусов О.Ю., Муксинова М.Д., Протасов В.Н., Протасова Д.Е., Кузнецова Т.В. и др. Клиническое значение серийного определения активности современных биомаркеров у больных после декомпенсации сердечной недостаточности: роль sST2 и NT-proBNP при длительном наблюдении. Кардиология. 2018;58(12S):27-41. DOI: 10.18087/cardio.2634Skvortsov A.A., Narusov O.Yu., Muksinova M.D., Protasov V.N., Protasova D.E., Kuznetsova T.V. et al. Clinical significance of serial biomarkers activity determination after acute heart failure decompensation: sST2 NTproBNP role during long-term follow-up. Kardiologiia. 2018;58(12S):27–41. DOI: 10.18087/cardio.2634Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364(1):11–21. DOI: 10.1056/NEJMoa1009492Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364(1):11–21. DOI: 10.1056/NEJMoa1009492Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149-218. DOI: 10.15829/1560-4071-2020-3-3786Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149–218. DOI: 10.15829/1560-4071-2020-3-3786Carey RM, Douglas JG, Schweikert JR, Liddle GW. The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone. Archives of Internal Medicine. 1972;130(6):849–54. PMID: 5082464Carey RM, Douglas JG, Schweikert JR, Liddle GW. The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone. Archives of Internal Medicine. 1972;130(6):849–54. PMID: 5082464Rodilla E, Costa JA, Pérez-Lahiguera F, Baldó E, González C, Pascual JM. Spironolactone and Doxazosin Treatment in Patients With Resistant Hypertension. Revista Española de Cardiología (English Edition). 2009;62(2):158–66. DOI: 10.1016/S1885-5857(09)71534-8Rodilla E, Costa JA, Pérez-Lahiguera F, Baldó E, González C, Pascual JM. Spironolactone and Doxazosin Treatment in Patients With Resistant Hypertension. Revista Española de Cardiología (English Edition). 2009;62(2):158–66. DOI: 10.1016/S1885-5857(09)71534-8Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension. 2007;25(4):891–4. DOI: 10.1097/HJH.0b013e328014954dLane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension. 2007;25(4):891–4. DOI: 10.1097/HJH.0b013e328014954dGaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. Journal of Human Hypertension. 2010;24(8):532–7. DOI: 10.1038/jhh.2009.96Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. Journal of Human Hypertension. 2010;24(8):532–7. DOI: 10.1038/jhh.2009.96Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of lowdose spironolactone on resistant hypertension. Journal ofthe American Society of Hypertension. 2010;4(6):290–4. DOI: 10.1016/j.jash.2010.10.001Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of lowdose spironolactone on resistant hypertension. Journal ofthe American Society of Hypertension. 2010;4(6):290–4. DOI: 10.1016/j.jash.2010.10.001Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension. 2007;49(4):839–45. DOI: 10.1161/01.HYP.0000259805.18468.8cChapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension. 2007;49(4):839–45. DOI: 10.1161/01.HYP.0000259805.18468.8cWilliams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. The Lancet Diabetes & Endocrinology. 2018;6(6):464–75. DOI: 10.1016/S2213-8587(18)30071-8Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. The Lancet Diabetes & Endocrinology. 2018;6(6):464–75. DOI: 10.1016/S2213-8587(18)30071-8Conn JW. Primary aldosteronism. The Journal of Laboratory and Clinical Medicine. 1955;45(4):661–4. PMID: 14368032Conn JW. Primary aldosteronism. The Journal of Laboratory and Clinical Medicine. 1955;45(4):661–4. PMID: 14368032Funder J. Primary aldosteronism. Trends in Cardiovascular Medicine. 2021;S1050-1738(21)00043-8. [Epub ahead of print]. DOI: 10.1016/j.tcm.2021.03.005Funder J. Primary aldosteronism. Trends in Cardiovascular Medicine. 2021;S1050-1738(21)00043-8. [Epub ahead of print]. DOI: 10.1016/j.tcm.2021.03.005Xu F, Gao Z, Wang G, Gao Y, Guo Y, Guo Y et al. Prevalence, Subtype Classification, and Outcomes of Treatment of Primary Aldosteronism: A Prospective Study in China. Endocrine Practice. 2021;27(5):478–83. DOI: 10.1016/j.eprac.2020.10.007Xu F, Gao Z, Wang G, Gao Y, Guo Y, Guo Y et al. Prevalence, Subtype Classification, and Outcomes of Treatment of Primary Aldosteronism: A Prospective Study in China. Endocrine Practice. 2021;27(5):478–83. DOI: 10.1016/j.eprac.2020.10.007Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Annals of Internal Medicine. 2020;173(1):10–20. DOI: 10.7326/M20-0065Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Annals of Internal Medicine. 2020;173(1):10–20. DOI: 10.7326/M20-0065Pilz S, Grübler MR, Theiler-Schwetz V, Malle O, Trummer C. The Unrecognized Prevalence of Primary Aldosteronism. Annals of Internal Medicine. 2020;173(8):681–2. DOI: 10.7326/L20-1094Pilz S, Grübler MR, Theiler-Schwetz V, Malle O, Trummer C. The Unrecognized Prevalence of Primary Aldosteronism. Annals of Internal Medicine. 2020;173(8):681–2. DOI: 10.7326/L20-1094Vaidya A, Carey RM. Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. The Journal of Clinical Endocrinology & Metabolism. 2020;105(12):3771–83. DOI: 10.1210/clinem/dgaa606Vaidya A, Carey RM. Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. The Journal of Clinical Endocrinology & Metabolism. 2020;105(12):3771–83. DOI: 10.1210/clinem/dgaa606Ruilope LM, Ruiz-Hurtado G, Tamargo J. Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. Trends in Cardiovascular Medicine. 2021;S1050-1738(21)00047-5. [Epub ahead of print]. DOI: 10.1016/j.tcm.2021.04.003Ruilope LM, Ruiz-Hurtado G, Tamargo J. Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. Trends in Cardiovascular Medicine. 2021;S1050-1738(21)00047-5. [Epub ahead of print]. DOI: 10.1016/j.tcm.2021.04.003Mehdi A, Rao P, Thomas G. Our evolving understanding of primary aldosteronism. Cleveland Clinic Journal of Medicine. 2021;88(4):221–7. DOI: 10.3949/ccjm.88a.20166Mehdi A, Rao P, Thomas G. Our evolving understanding of primary aldosteronism. Cleveland Clinic Journal of Medicine. 2021;88(4):221–7. DOI: 10.3949/ccjm.88a.20166Kaneko H, Umakoshi H, Ogata M, Wada N, Iwahashi N, Fukumoto T et al. Machine learning based models for prediction of subtype diagnosis of primary aldosteronism using blood test. Scientific Reports. 2021;11(1):9140. DOI: 10.1038/s41598-021-88712-8Kaneko H, Umakoshi H, Ogata M, Wada N, Iwahashi N, Fukumoto T et al. Machine learning based models for prediction of subtype diagnosis of primary aldosteronism using blood test. Scientific Reports. 2021;11(1):9140. DOI: 10.1038/s41598-021-88712-8Li N, Huang J, Zheng B, Cai H, Liu M, Liu L. Cost‐effectiveness Analysis of Screening for Primary Aldosteronism in China. Clinical Endocrinology. 2021;95(3):414–22. DOI: 10.1111/cen.14478Li N, Huang J, Zheng B, Cai H, Liu M, Liu L. Cost‐effectiveness Analysis of Screening for Primary Aldosteronism in China. Clinical Endocrinology. 2021;95(3):414–22. DOI: 10.1111/cen.14478Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052Mackey K, King VJ, Gurley S, Kiefer M, Liederbauer E, Vela K et al. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review. Annals of Internal Medicine. 2020;173(3):195–203. DOI: 10.7326/M20-1515Mackey K, King VJ, Gurley S, Kiefer M, Liederbauer E, Vela K et al. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review. Annals of Internal Medicine. 2020;173(3):195–203. DOI: 10.7326/M20-1515Chen Z-W, Tsai C-H, Pan C-T, Chou C-H, Liao C-W, Hung C-S et al. Endothelial Dysfunction in Primary Aldosteronism. International Journal of Molecular Sciences. 2019;20(20):5214. DOI: 10.3390/ijms20205214Chen Z-W, Tsai C-H, Pan C-T, Chou C-H, Liao C-W, Hung C-S et al. Endothelial Dysfunction in Primary Aldosteronism. International Journal of Molecular Sciences. 2019;20(20):5214. DOI: 10.3390/ijms20205214Vicenzi M, Di Cosola R, Ruscica M, Ratti A, Rota I, Rota F et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. European Respiratory Journal. 2020;56(1):2001157. DOI: 10.1183/13993003.01157-2020Vicenzi M, Di Cosola R, Ruscica M, Ratti A, Rota I, Rota F et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. European Respiratory Journal. 2020;56(1):2001157. DOI: 10.1183/13993003.01157-2020Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. New England Journal of Medicine. 2020;383(2):120–8. DOI: 10.1056/NEJMoa2015432Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. New England Journal of Medicine. 2020;383(2):120–8. DOI: 10.1056/NEJMoa2015432Wang J, Wang BJ, Yang JC, Wang MY, Chen C, Luo GX et al. Research advances in the mechanism of pulmonary fibrosis induced by coronavirus disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi. 2020;36(8):691–7. DOI: 10.3760/cma.j.cn501120-20200307-00132Wang J, Wang BJ, Yang JC, Wang MY, Chen C, Luo GX et al. Research advances in the mechanism of pulmonary fibrosis induced by coronavirus disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi. 2020;36(8):691–7. DOI: 10.3760/cma.j.cn501120-20200307-00132Zhao H, Gu DW, Li HT, Ge QF, Li GP. Inhibitory effects of spironolactone on myocardial fibrosis in spontaneously hypertensive rats. Genetics and Molecular Research. 2015;14(3):10315–21. DOI: 10.4238/2015.August.28.17Zhao H, Gu DW, Li HT, Ge QF, Li GP. Inhibitory effects of spironolactone on myocardial fibrosis in spontaneously hypertensive rats. Genetics and Molecular Research. 2015;14(3):10315–21. DOI: 10.4238/2015.August.28.17Funder JW. Spironolactone in cardiovascular disease: an expanding universe? F1000Research. 2017;6:1738. DOI: 10.12688/f1000research.11887.1Funder JW. Spironolactone in cardiovascular disease: an expanding universe? F1000Research. 2017;6:1738. DOI: 10.12688/f1000research.11887.1Yavas G, Yavas C, Celik E, Sen E, Ata O, Afsar RE. The impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapy. International Journal of Radiation Research. 2019;17(1):87–95. DOI: 10.18869/acadpub.ijrr.17.1.87Yavas G, Yavas C, Celik E, Sen E, Ata O, Afsar RE. The impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapy. International Journal of Radiation Research. 2019;17(1):87–95. DOI: 10.18869/acadpub.ijrr.17.1.87Ji W-J, Ma Y-Q, Zhou X, Zhang Y-D, Lu R-Y, Guo Z-Z et al. Spironolactone Attenuates Bleomycin-Induced Pulmonary Injury Partially via Modulating Mononuclear Phagocyte Phenotype Switching in Circulating and Alveolar Compartments. PLoS ONE. 2013;8(11):e81090. DOI: 10.1371/journal.pone.0081090Ji W-J, Ma Y-Q, Zhou X, Zhang Y-D, Lu R-Y, Guo Z-Z et al. Spironolactone Attenuates Bleomycin-Induced Pulmonary Injury Partially via Modulating Mononuclear Phagocyte Phenotype Switching in Circulating and Alveolar Compartments. PLoS ONE. 2013;8(11):e81090. DOI: 10.1371/journal.pone.0081090Barut F, Ozacmak VH, Turan I, Sayan-Ozacmak H, Aktunc E. Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. Clinical & Investigative Medicine. 2016;39(1):E15-24. DOI: 10.25011/cim.v39i1.26326Barut F, Ozacmak VH, Turan I, Sayan-Ozacmak H, Aktunc E. Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. Clinical & Investigative Medicine. 2016;39(1):E15-24. DOI: 10.25011/cim.v39i1.26326Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. 2020. [Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.03.30.20047878].Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. 2020. [Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.03.30.20047878].Atalay C, Dogan N, Aykan S, Gundogdu C, Keles MS. The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. Singapore Medical Journal. 2010;51(6):501–5. PMID: 20658111Atalay C, Dogan N, Aykan S, Gundogdu C, Keles MS. The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. Singapore Medical Journal. 2010;51(6):501–5. PMID: 20658111Chen D, Li X, Song Q, Hu C, Su F, Dai J et al. Assessment of Hypokalemia and Clinical Characteristics in Patients with Coronavirus Disease 2019 in Wenzhou, China. JAMA Network Open. 2020;3(6):e2011122. DOI: 10.1001/jamanetworkopen.2020.11122Chen D, Li X, Song Q, Hu C, Su F, Dai J et al. Assessment of Hypokalemia and Clinical Characteristics in Patients with Coronavirus Disease 2019 in Wenzhou, China. JAMA Network Open. 2020;3(6):e2011122. DOI: 10.1001/jamanetworkopen.2020.11122Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine. 2004;351(6):543–51. DOI: 10.1056/NEJMoa040135Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine. 2004;351(6):543–51. DOI: 10.1056/NEJMoa040135Villard O, Morquin D, Molinari N, Raingeard I, Nagot N, Cristol J-P et al. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. Journal of Clinical Medicine. 2020;9(7):2315. DOI: 10.3390/jcm9072315Villard O, Morquin D, Molinari N, Raingeard I, Nagot N, Cristol J-P et al. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. Journal of Clinical Medicine. 2020;9(7):2315. DOI: 10.3390/jcm9072315Jeon D, Son M, Choi J. Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea. Frontiers in Medicine. 2021;8:629176. DOI: 10.3389/fmed.2021.629176Jeon D, Son M, Choi J. Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea. Frontiers in Medicine. 2021;8:629176. DOI: 10.3389/fmed.2021.629176Мареев В.Ю., Орлова Я.А., Плисюк А.Г., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А. и др. Результаты открытого проспективного контролируемого сравнительного исследования по лечению новой коронавирусной инфекции (COVID-19): Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(11):4-15. DOI: 10.18087/cardio.2020.11.1440Mareev V.Yu., Orlova Ya.A., Plisyk A.G., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A. et al. Results of an open prospective controlled comparative study on the treatment of new coronavirus infection (COVID-19): Bromhexine and spironolactone for the treatment of coronavirus Infection requiring hospitalization (BISCUIT). Kardiologiia. 2020;60(11):4–15. DOI: 10.18087/cardio.2020.11.1440Мареев В.Ю., Орлова Я.А., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А., Плисюк А.Г. и др. Возможности комбинированной терапии на раннем этапе течения новой коронавирусной инфекции (COVID-19). Разбор клинических случаев и дизайн исследования: Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(8):4–15. DOI: 10.18087/cardio.2020.8.n1307Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A., Plisyk A.G. et al. Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronavirUs Infection requiring hospiTalization (BISCUIT)”. Kardiologiia. 2020;60(8):4–15. DOI: 10.18087/cardio.2020.8.n1307Vicenzi M, Ruscica M, Iodice S, Rota I, Ratti A, Di Cosola R et al. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. Journal of Clinical Medicine. 2020;9(9):2943. DOI: 10.3390/jcm9092943Vicenzi M, Ruscica M, Iodice S, Rota I, Ratti A, Di Cosola R et al. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. Journal of Clinical Medicine. 2020;9(9):2943. DOI: 10.3390/jcm9092943

The authors declare that there are no conflicts of interest present.